hydroxyurea has been researched along with Primary Myelofibrosis in 140 studies
Primary Myelofibrosis: A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxyurea (HU) treatment of patients with essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) (MPNs) normalizes elevated blood cell counts within weeks in the large majority of patients." | 9.41 | Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis. ( Andersen, M; Dam, MJB; Hasselbalch, HC; Kjaer, L; Knudsen, TA; Ottesen, JT; Pedersen, RK; Skov, V, 2021) |
| "Hydroxyurea is the standard treatment in high-risk patients with polycythemia vera." | 9.01 | Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. ( Barbui, T; Carobbio, A; De Stefano, V; Ferrari, A; Finazzi, G; Ghirardi, A; Masciulli, A; Vannucchi, AM, 2019) |
| "A 73-year-old man with primary myelofibrosis (PMF) was being treated with hydroxyurea, which was changed to ruxolitinib treatment because of worsening constitutional symptoms." | 8.98 | Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature. ( Ikeda, M; Kiyasu, J; Ogawa, Y; Shiratsuchi, M; Tsuda, M; Tsukamoto, Y; Yufu, Y, 2018) |
| "Medication-induced dermatomyositis (DM) is rare, but a recent review highlighted hydroxyurea (HU) as the most common inciting agent." | 8.88 | Hydroxyurea induced dermatomyositis-like eruption. ( Muir, J; Rodins, K; Zappala, TM, 2012) |
| "Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown." | 8.12 | Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. ( Alvarez-Larrán, A; Angona, A; Arellano-Rodrigo, E; Ayala, R; Bellosillo, B; Caballero, G; Carreño-Tarragona, G; Cuevas, B; Del Orbe-Barreto, R; Ferrer-Marín, F; Fox, ML; García, R; García-Gutiérrez, V; García-Hernández, C; Garrote, M; Gasior, M; Gómez, M; Gómez-Casares, MT; Guerrero, L; Hernández-Boluda, JC; Magro, E; Martínez, CM; Mata-Vazquez, MI; Murillo, I; Pereira, A; Pérez-Encinas, M; Pérez-López, R; Ramírez, MJ; Raya, JM; Xicoy, B, 2022) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 7.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 7.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "We report four cases of cutaneous lower leg ulcers associated with hydroxyurea treatment for myeloproliferative disorders." | 7.68 | Hydroxyurea and lower leg ulcers. ( Margolis, DJ; Nguyen, TV, 1993) |
| "An analysis of the risk of progression towards leukemia, carcinoma and myelofibrosis was performed in 93 patients treated by 32P alone (PVSG protocols) since 1970-1979, 395 patients over the age of 65 years treated by 32P with or without maintenance therapy using hydroxyurea (French protocol) since 1980-1994, and 202 patients under the age of 65 treated by either hydroxyurea or pipobroman since 1980." | 6.18 | Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". ( Dresch, C; Echard, M; Goguel, A; Grange, MJ; Lejeune, F; Najean, Y; Rain, JD, 1996) |
| "Paediatric primary myelofibrosis (PMF) is exceedingly rare and distinct compared with adult PMF." | 5.91 | Complete resolution of primary myelofibrosis in an infant with steroids and hydroxyurea. ( Khera, S; Misra, P; Singh, K; Tripathi, P, 2023) |
| "Hydroxyurea (HU) treatment of patients with essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) (MPNs) normalizes elevated blood cell counts within weeks in the large majority of patients." | 5.41 | Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis. ( Andersen, M; Dam, MJB; Hasselbalch, HC; Kjaer, L; Knudsen, TA; Ottesen, JT; Pedersen, RK; Skov, V, 2021) |
| "A case of idiopathic myelofibrosis presenting with a pleural effusion secondary to extramedullary haemopoeisis is described." | 5.30 | Pleural effusion secondary to extramedullary haemopoiesis in a patient with idiopathic myelofibrosis responding to pleurodesis and hydroxyurea. ( Burke, DK; Cryer, RJ; Jowitt, SN; Leggat, HM; Lewis, PS, 1997) |
| "Treatment with hydroxyurea was followed by a marked reduction in spleen size, a decrease in white cell count and healing of the skin lesions." | 5.26 | Chronic granulocytic leukemia cutis treated with hydroxyurea. Report of a case. ( Atamer, MA; Friedhoff, FW; Thelmo, WL, 1978) |
| " As compared with hydroxyurea plus aspirin, anagrelide plus aspirin was associated with increased rates of arterial thrombosis (P=0." | 5.11 | Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. ( Bareford, D; Buck, G; Campbell, PJ; East, CL; Green, AR; Grigg, AP; Harrison, CN; Reilly, JT; Revell, P; van der Walt, JD; Wheatley, K; Wilkins, BS; Woodcock, BE, 2005) |
| "Hydroxyurea is the standard treatment in high-risk patients with polycythemia vera." | 5.01 | Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. ( Barbui, T; Carobbio, A; De Stefano, V; Ferrari, A; Finazzi, G; Ghirardi, A; Masciulli, A; Vannucchi, AM, 2019) |
| "A 73-year-old man with primary myelofibrosis (PMF) was being treated with hydroxyurea, which was changed to ruxolitinib treatment because of worsening constitutional symptoms." | 4.98 | Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature. ( Ikeda, M; Kiyasu, J; Ogawa, Y; Shiratsuchi, M; Tsuda, M; Tsukamoto, Y; Yufu, Y, 2018) |
| " An algorithm for the treatment of patients with erythremia is proposed along with recommendations on the use of aspirin, hydroxyurea, alpha-interpheron, and imatinib." | 4.88 | [True polycythemia: current views of pathogenesis, diagnostics and treatment]. ( Bakhteeva, TD; Kalinkina, NV; Skliannaia, EV; Taradin, GG; Vatutin, NT, 2012) |
| "Medication-induced dermatomyositis (DM) is rare, but a recent review highlighted hydroxyurea (HU) as the most common inciting agent." | 4.88 | Hydroxyurea induced dermatomyositis-like eruption. ( Muir, J; Rodins, K; Zappala, TM, 2012) |
| " Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P." | 4.80 | Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998) |
| " Treatment selection is based on a patient's age and a history of thrombosis in patients with low-risk PV treated with therapeutic phlebotomy and aspirin alone, whereas cytoreductive therapy with either hydroxyurea or interferon alfa (IFN-α) is added for high-risk disease." | 4.31 | Moving toward disease modification in polycythemia vera. ( Bewersdorf, JP; Bose, P; How, J; Masarova, L; Mascarenhas, J; Pemmaraju, N; Rampal, RK, 2023) |
| "Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown." | 4.12 | Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. ( Alvarez-Larrán, A; Angona, A; Arellano-Rodrigo, E; Ayala, R; Bellosillo, B; Caballero, G; Carreño-Tarragona, G; Cuevas, B; Del Orbe-Barreto, R; Ferrer-Marín, F; Fox, ML; García, R; García-Gutiérrez, V; García-Hernández, C; Garrote, M; Gasior, M; Gómez, M; Gómez-Casares, MT; Guerrero, L; Hernández-Boluda, JC; Magro, E; Martínez, CM; Mata-Vazquez, MI; Murillo, I; Pereira, A; Pérez-Encinas, M; Pérez-López, R; Ramírez, MJ; Raya, JM; Xicoy, B, 2022) |
| " 2004 and treated with hydroxyurea (HU), was admitted to our hospital on March 2005 because of dyspnea and pleural effusion on the right side." | 3.73 | [Low dose whole lung irradiation for intractable pleural effusion due to idiopathic myelofibrosis]. ( Dan, K; Inokuchi, K; Nakamura, K; Okabe, M; Tajika, K; Takeuchi, J; Tamai, H; Wakita, S; Yamaguchi, H, 2006) |
| "Imatinib mesylate has been reported to produce positive results in atypical chronic myeloproliferative disorders (CMD) with chromosomal translocations that disrupt the platelet-derived growth factor receptor beta gene (PDGFRB)." | 3.72 | Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene. ( Bastie, JN; Castaigne, S; Cross, NC; Garcia, I; Mahon, FX; Terré, C, 2004) |
| "Eighty-three patients with various chronic myeloproliferative disorders [polycythemia vera (PV), essential thrombocytosis (ET), idiopathic myelofibrosis (IMF)] were analyzed for the occurrence of acute myeloid leukemia (AML) and myelodysplasia (MDS) during treatment with hydroxyurea (HU) alone or HU following treatment with busulphan (BU)." | 3.72 | Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. ( Hasselbalch, HC; Nielsen, I, 2003) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 3.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "A patient with idiopathic myelofibrosis is reported who developed a drug fever after treatment with hydroxyurea, a generally effective and well-tolerated drug in chronic myeloproliferative syndromes." | 3.69 | An unwanted side effect of hydroxyurea in a patient with idiopathic myelofibrosis. ( Fickers, MM; Pannebakker, MA; Starmans-Kool, MJ, 1995) |
| "We report four cases of cutaneous lower leg ulcers associated with hydroxyurea treatment for myeloproliferative disorders." | 3.68 | Hydroxyurea and lower leg ulcers. ( Margolis, DJ; Nguyen, TV, 1993) |
| "A case of idiopathic myelofibrosis (IMF) presenting with hypercalcemia and hypercalcitriolemia is reported." | 3.68 | Hypercalcemia in idiopathic myelofibrosis: modulation of calcium and collagen homeostasis by 1,25-dihydroxyvitamin D3. ( Hasselbalch, H; Junker, P; Schmidt, K; Voss, A, 1992) |
| " We examined Hb F in 13 patients with myeloproliferative disease (six polycythemia vera, five polycythemia vera with myeloid metaplasia, one agnogenic myeloid metaplasia, and one chronic myelogenous leukemia) who were treated with hydroxyurea." | 3.67 | The effect of hydroxyurea on hemoglobin F in patients with myeloproliferative syndromes. ( Alter, BP; Gilbert, HS, 1985) |
| "In idiopathic myelofibrosis (IMF) PDGF is considered to be one of the growth factors responsible for the development of bone marrow fibrosis." | 2.71 | Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. ( Birgens, H; Bjerrum, OW; Clausen, NT; Hansen, PB; Hasselbalch, HC; Jensen, BA; Ralfkiaer, E; Therkildsen, MH, 2003) |
| "Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms, respectively characterized by erythrocytosis and thrombocytosis." | 2.52 | Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2015) |
| "Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage." | 2.49 | [Treatment of essential thrombocythemia]. ( Alvarez-Larrán, A; Besses, C; Cervantes, F, 2013) |
| "Development of myelofibrosis in IMF is obviously due to disease progression unrelated to stage at diagnosis and not significantly influenced by treatment modalities." | 2.42 | Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis. ( Diehl, V; Hülsemann, R; Kvasnicka, HM; Schmitt-Gräff, A; Thiele, J, 2004) |
| "Median survival of patients with myelofibrosis with myeloid metaplasia (MMM) ranges from 3." | 2.41 | Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000. ( Cervantes, F, 2001) |
| "We report a case of myelofibrosis with myeloid metaplasia (MMM) that responded dramatically to oral busulfan treatment after failure of hydroxyurea." | 2.41 | Myelofibrosis: response to busulfan after hydroxyurea failure. ( Baumann, MA; Naqvi, T, 2002) |
| "Idiopathic myelofibrosis is the least common and carries the worst prognosis of the chronic myeloproliferative disorders." | 2.40 | Pathogenesis and management of idiopathic myelofibrosis. ( Reilly, JT, 1998) |
| "Idiopathic myelofibrosis is reviewed from several aspects." | 2.38 | Idiopathic myelofibrosis: historical review, diagnosis and management. ( Weinstein, IM, 1991) |
| "Primary myelofibrosis (PM) is one of the myeloproliferative neoplasm, where stem cell-derived clonal neoplasms was noticed." | 1.91 | Detection of primary myelofibrosis in blood serum via Raman spectroscopy assisted by machine learning approaches; correlation with clinical diagnosis. ( Aday, A; Bayrak, AG; Ceylan, Z; Depciuch, J; Guleken, Z; Hindilerden, İY; Jakubczyk, D; Jakubczyk, P; Kula-Maximenko, M; Nalçacı, M, 2023) |
| "Pruritus was reported by 49." | 1.91 | Differences between aquagenic and non-aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients. ( Ficheux, AS; Herbreteau, L; Ianotto, JC; Le Gall-Ianotto, C; Lippert, E; Misery, L; Pan-Petesch, B; Rio, L, 2023) |
| "Paediatric primary myelofibrosis (PMF) is exceedingly rare and distinct compared with adult PMF." | 1.91 | Complete resolution of primary myelofibrosis in an infant with steroids and hydroxyurea. ( Khera, S; Misra, P; Singh, K; Tripathi, P, 2023) |
| "Within the 1258 SMF of the MYSEC (MYelofibrosis SECondary to PV and ET) dataset, 135 (10." | 1.72 | Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients. ( Albano, F; Arcaini, L; Auteri, G; Barbui, T; Benevolo, G; Bertù, L; Brociner, M; Caramazza, D; Caramella, M; Casetti, IC; Cattaneo, D; Cervantes, F; De Stefano, V; Della Porta, MG; Devos, T; Gotlib, J; Guglielmelli, P; Iurlo, A; Kiladjian, JJ; Komrokji, RS; Kuykendall, A; Maffioli, M; Merli, M; Mora, B; Palandri, F; Passamonti, F; Ross, DM; Rotunno, G; Ruggeri, M; Rumi, E; Salmoiraghi, S; Silver, RT; Vannucchi, AM, 2022) |
| "The pleural effusion was transudative, although there was no history of cardiac failure or hypoalbuminemia, and treatment with diuretics failed." | 1.62 | Transudative Pleural Effusion Associated with Extramedullary Hematopoiesis. ( Amaki, J; Aoki, T; Asano, K; Enokida, K; Hayama, N; Oguma, T; Okada, N; Takeuchi, T; Takihara, T; Tomomatsu, K, 2021) |
| "We report here 53 myelofibrosis patients that received a combination of hydroxyurea and ruxolitinib because of uncontrolled myeloproliferation." | 1.51 | Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. ( Benevolo, G; Binotto, G; Bonifacio, M; Breccia, M; Caocci, G; Cavo, M; De Stefano, V; Foà, R; Latagliata, R; Luciano, L; Martinelli, V; Martino, B; Palandri, F; Pane, F; Pugliese, N; Rossi, E; Scalzulli, E; Tiribelli, M, 2019) |
| "Cases (n = 647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological second cancer, and melanoma) and controls (n = 1234) were patients without SC, matched with cases for sex, age at MPN diagnosis, date of MPN diagnosis, and MPN disease duration." | 1.51 | Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. ( Alvarez-Larran, A; Angona, A; Barbui, T; Beggiato, E; Benevolo, G; Bertolotti, L; Betti, S; Bonifacio, M; Cacciola, R; Carli, G; Carobbio, A; Casetti, IC; Cattaneo, D; De Stefano, V; Delaini, F; Di Veroli, A; Elli, EM; Erez, D; Finazzi, G; Fox, ML; Ghirardi, A; Gomez, M; Griesshammer, M; Guglielmelli, P; Iurlo, A; Lunghi, F; Marchetti, M; Masciulli, A; McMullin, MF; Palandri, F; Palova, M; Patriarca, A; Perez-Encinas, M; Recasens, V; Rumi, E; Scaffidi, L; Stephenson, C; Tieghi, A; Vannucchi, AM; Vianelli, N; Wille, K, 2019) |
| " The number of patients requiring ruxolitinib dosage reduction or discontinuations was lower during combination therapy and, at the end of follow-up the median ruxolitinib dose was increased in 50% of patients." | 1.51 | Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis. ( Annunziata, M; Casale, B; Cerchione, C; Crisà, E; Giordano, C; Grimaldi, F; Iovine, M; Luciano, L; Martinelli, V; Nappi, D; Pane, F; Pezzullo, L; Picardi, M; Pugliese, N; Villa, MR, 2019) |
| "Risk of thrombosis is higher in JAK2-mutated ET." | 1.51 | Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019) |
| "Myelofibrosis was treated with hydroxyurea." | 1.51 | Development of myelofibrosis and acute monocytic leukemia in a patient with hereditary spherocytosis: A case report. ( Liu, H; Qian, J; Shen, Q; Shi, WY; Yang, L; Yin, H; Zhang, YP, 2019) |
| "Polycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation." | 1.46 | Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. ( Barbui, T; Tefferi, A, 2017) |
| "Hydroxyurea was the most commonly used cytoreductive therapy." | 1.46 | Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. ( Bilgir, O; Çağlıyan, G; Çekdemir, D; Cömert, M; Haznedaroğlu, İC; İlhan, O; Kaya, E; Özdemirkıran, F; Şahin, F; Saydam, G; Soyer, N; Ünal, A; Vural, F; Yılmaz, M, 2017) |
| "We report a case of membranous nephropathy accompanied by kidney injury in a patient with primary myelofibrosis with additional features considered related to the patient's myeloproliferative disorder." | 1.46 | Membranous Nephropathy and Intrarenal Extramedullary Hematopoiesis in a Patient With Myelofibrosis. ( Aniort, J; Heng, AE; Kemeny, JL; Philipponnet, C; Ronco, P, 2017) |
| "Chronic inflammation is suggested to contribute to the Philadelphia-chromosome-negative myeloproliferative neoplasm (MPN) disease initiation and progression, as well as the development of premature atherosclerosis and may drive the development of other cancers in MPNs, both nonhematologic and hematologic." | 1.40 | Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. ( Hasselbalch, HC, 2014) |
| "Diagnosis of post-PV myelofibrosis is established according to the International Working Group for Myeloproliferative Neoplasms Research and Treatment criteria." | 1.38 | How I treat polycythemia vera. ( Passamonti, F, 2012) |
| "A case of a 69-year-old woman with myelofibrosis presenting with non-small cell lung cancer was reported at Sotiria General Hospital in Athens." | 1.36 | Bevacizumab may be active in myelofibrosis. ( Dilana, K; Makrilia, N; Meletis, I; Nikolaidis, I; Stathopoulos, D; Syrigos, K; Xyla, V, 2010) |
| "The underlying cause was polycythemia rubra vera and osteomyolofibrosis." | 1.35 | [Budd-Chiari syndrome--from diagnosis to treatment--case reports]. ( Dybowska, D; Kozielewicz, D; Smukalska, E, 2008) |
| "Agnogenic myeloid metaplasia (AMM) is characterized by bone marrow fibrosis, splenomegaly and leukoerythroblastic anemia and is frequently accompanied by extramedullary hematopoiesis (EMH)." | 1.33 | Agnogenic myeloid metaplasia with pulmonary hematopoiesis. ( Boula, A; Foudoulakis, A; Mantadakis, E; Samonis, G; Xilouri, I, 2005) |
| "Granulocytic sarcoma is very rare in essential thrombocythemia, and this patient may be the first reported case of essential thrombocythemia that developed multiple lesions and a pathologic fracture without transformation to overt leukemia." | 1.33 | Multiple granulocytic sarcomas in essential thrombocythemia. ( Fujita, H; Kurata, M; Maeda, A; Matsushita, A; Mori, M; Nagai, K; Nagai, Y; Takahashi, T; Tanaka, K; Tanaka, Y; Togami, K, 2006) |
| "Hydroxyurea and myelosan were mostly used as cytostatic drugs while erythrocyte mass transfusions and hemoexfusions (phlebotomy)--for life-support." | 1.32 | [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases]. ( Pop, VP; Rukavitsyn, OA; Seriakov, AP, 2004) |
| "Controversial issues in chronic idiopathic myelofibrosis (IMP) are amongst others the evolution of the disease process and the influence of therapy on the dynamics of fibrosis." | 1.32 | Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. ( Diehl, V; Kvasnicka, HM; Schmitt-Graeff, A; Thiele, J, 2003) |
| "Hydroxyurea (HU) is a good-controllable and well-tolerated cytostatic drug." | 1.32 | [Hydroxyurea-induced pneumonitis]. ( Schwonzen, M; Spangenberger, H; Spengler, M, 2003) |
| "A 60-year-old white woman with polycythemia rubra vera post splenectomy in November 2001 was found to have peripheral white blood cell counts increasing over 3 months." | 1.32 | Paraneoplastic eosinophilic fasciitis: a case report. ( Cohen, JJ; Jacob, SE; Kirsner, RS; Lodha, R; Romanelli, P, 2003) |
| "A 70-year-old man with primary myelofibrosis was treated with hydroxycarbamide and blood transfusions." | 1.31 | [Diagnostic image (117). A man with frequent blood transfusion and blister on his fingers. A form of porpheria cutanea tarda caused by excess iron]. ( Jonkhoff, AR; van der Valk, P; Zweegman, S, 2002) |
| "Of the 124 patients without myelofibrosis at onset, 42% later transformed into the myelofibrotic subtype." | 1.31 | Changing patterns of histological subgroups during therapy of Ph1+ chronic myelogenous leukaemia. ( Kvasnicka, HM; Leder, LD; Schaefer, HE; Schmitt-Graeff, A; Thiele, J, 2000) |
| "A case of idiopathic myelofibrosis presenting with a pleural effusion secondary to extramedullary haemopoeisis is described." | 1.30 | Pleural effusion secondary to extramedullary haemopoiesis in a patient with idiopathic myelofibrosis responding to pleurodesis and hydroxyurea. ( Burke, DK; Cryer, RJ; Jowitt, SN; Leggat, HM; Lewis, PS, 1997) |
| "We found a significant reduction of bone marrow fibrosis, believed to be mediated by suppression of thrombopoiesis by hydroxyurea." | 1.28 | Reversal of myelofibrosis by hydroxyurea. ( Löfvenberg, E; Ost, A; Roos, G; Wahlin, A, 1990) |
| "Seventeen patients with either chronic myelogenous leukemia (CML) or myelofibrosis with myeloid metaplasia (MMM) received 24 courses of splenic irradiation at this institution from 1973 to 1982." | 1.27 | Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia. Results of daily and intermittent fractionation with and without concomitant hydroxyurea. ( Desforges, J; Madoc-Jones, H; McKeough, PG; Wagner, H, 1986) |
| "A patient with postpolycythemic myeloid metaplasia who previously underwent splenectomy presented with recurrent, protracted gastrointestinal tract hemorrhage." | 1.27 | Small intestinal myeloid metaplasia. ( Alroy, G; Ben-Arieh, Y; Brenner, B; Jacobs, R; Schreibman, D; Tatarsky, I, 1988) |
| "Treatment with hydroxyurea was followed by a dramatic response of both the polycythemia vera and the HES, with return to normal of the abnormal immunologic measures." | 1.27 | Hypereosinophilic syndrome associated with polycythemia vera. ( Berrebi, A; Varon, D; Wetzler, M, 1986) |
| "Treatment with hydroxyurea was followed by a marked reduction in spleen size, a decrease in white cell count and healing of the skin lesions." | 1.26 | Chronic granulocytic leukemia cutis treated with hydroxyurea. Report of a case. ( Atamer, MA; Friedhoff, FW; Thelmo, WL, 1978) |
| "Hydroxyurea is an effective agent in the treatment of chronic myelogenous leukemia." | 1.25 | Skin changes secondary to hydroxyurea therapy. ( Goltz, RW; Kennedy, BJ; Smith, LR, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (9.29) | 18.7374 |
| 1990's | 21 (15.00) | 18.2507 |
| 2000's | 44 (31.43) | 29.6817 |
| 2010's | 47 (33.57) | 24.3611 |
| 2020's | 15 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Sekhri, R | 1 |
| Sadjadian, P | 1 |
| Becker, T | 1 |
| Kolatzki, V | 1 |
| Huenerbein, K | 1 |
| Meixner, R | 1 |
| Marchi, H | 1 |
| Wallmann, R | 1 |
| Fuchs, C | 1 |
| Griesshammer, M | 3 |
| Wille, K | 2 |
| Gerds, AT | 2 |
| Lyons, RM | 1 |
| Colucci, P | 1 |
| Kalafut, P | 1 |
| Paranagama, D | 1 |
| Verstovsek, S | 2 |
| Alvarez-Larrán, A | 4 |
| Garrote, M | 1 |
| Ferrer-Marín, F | 1 |
| Pérez-Encinas, M | 2 |
| Mata-Vazquez, MI | 1 |
| Bellosillo, B | 1 |
| Arellano-Rodrigo, E | 3 |
| Gómez, M | 2 |
| García, R | 1 |
| García-Gutiérrez, V | 1 |
| Gasior, M | 1 |
| Cuevas, B | 1 |
| Angona, A | 2 |
| Gómez-Casares, MT | 1 |
| Martínez, CM | 1 |
| Magro, E | 1 |
| Ayala, R | 1 |
| Del Orbe-Barreto, R | 1 |
| Pérez-López, R | 1 |
| Fox, ML | 2 |
| Raya, JM | 1 |
| Guerrero, L | 1 |
| García-Hernández, C | 1 |
| Caballero, G | 1 |
| Murillo, I | 1 |
| Xicoy, B | 1 |
| Ramírez, MJ | 1 |
| Carreño-Tarragona, G | 1 |
| Hernández-Boluda, JC | 1 |
| Pereira, A | 1 |
| Mora, B | 3 |
| Guglielmelli, P | 4 |
| Kuykendall, A | 1 |
| Rumi, E | 2 |
| Maffioli, M | 3 |
| Palandri, F | 3 |
| De Stefano, V | 4 |
| Caramella, M | 1 |
| Salmoiraghi, S | 2 |
| Kiladjian, JJ | 1 |
| Gotlib, J | 2 |
| Iurlo, A | 2 |
| Cervantes, F | 5 |
| Ruggeri, M | 1 |
| Silver, RT | 1 |
| Albano, F | 1 |
| Benevolo, G | 3 |
| Ross, DM | 1 |
| Della Porta, MG | 1 |
| Devos, T | 1 |
| Rotunno, G | 3 |
| Komrokji, RS | 1 |
| Casetti, IC | 2 |
| Merli, M | 1 |
| Brociner, M | 1 |
| Caramazza, D | 1 |
| Auteri, G | 1 |
| Barbui, T | 9 |
| Cattaneo, D | 2 |
| Bertù, L | 1 |
| Arcaini, L | 1 |
| Vannucchi, AM | 7 |
| Passamonti, F | 5 |
| Le Gall-Ianotto, C | 1 |
| Ficheux, AS | 1 |
| Lippert, E | 1 |
| Herbreteau, L | 1 |
| Rio, L | 1 |
| Pan-Petesch, B | 1 |
| Misery, L | 1 |
| Ianotto, JC | 1 |
| Guleken, Z | 1 |
| Ceylan, Z | 1 |
| Aday, A | 1 |
| Bayrak, AG | 1 |
| Hindilerden, İY | 1 |
| Nalçacı, M | 1 |
| Jakubczyk, P | 1 |
| Jakubczyk, D | 1 |
| Kula-Maximenko, M | 1 |
| Depciuch, J | 1 |
| Bewersdorf, JP | 1 |
| How, J | 1 |
| Masarova, L | 1 |
| Bose, P | 1 |
| Pemmaraju, N | 1 |
| Mascarenhas, J | 1 |
| Rampal, RK | 1 |
| Khera, S | 1 |
| Misra, P | 1 |
| Singh, K | 1 |
| Tripathi, P | 1 |
| Schain, F | 1 |
| Vago, E | 1 |
| Song, C | 1 |
| He, J | 1 |
| Liwing, J | 1 |
| Löfgren, C | 1 |
| Björkholm, M | 2 |
| Okuyucu, M | 1 |
| Atay, MH | 1 |
| Qian, J | 1 |
| Shen, Q | 1 |
| Yin, H | 1 |
| Shi, WY | 1 |
| Yang, L | 1 |
| Zhang, YP | 1 |
| Liu, H | 1 |
| Enokida, K | 1 |
| Tomomatsu, K | 1 |
| Okada, N | 1 |
| Takeuchi, T | 1 |
| Takihara, T | 1 |
| Amaki, J | 1 |
| Hayama, N | 1 |
| Oguma, T | 1 |
| Aoki, T | 1 |
| Asano, K | 1 |
| Loscocco, GG | 1 |
| Antonioli, E | 1 |
| Romano, I | 1 |
| Vergoni, F | 1 |
| Mannelli, F | 2 |
| Choi, HS | 1 |
| Hong, J | 1 |
| Hwang, SM | 1 |
| Lee, JH | 1 |
| Ma, Y | 1 |
| Kim, SA | 1 |
| Lee, JY | 1 |
| Lee, JO | 2 |
| Bang, SM | 2 |
| Huang, X | 1 |
| Ma, T | 1 |
| Zhu, Y | 1 |
| Jiao, B | 1 |
| Yu, S | 1 |
| Wang, K | 1 |
| Mi, JQ | 1 |
| Ren, R | 1 |
| Dam, MJB | 1 |
| Pedersen, RK | 1 |
| Knudsen, TA | 1 |
| Andersen, M | 1 |
| Skov, V | 1 |
| Kjaer, L | 1 |
| Hasselbalch, HC | 6 |
| Ottesen, JT | 1 |
| Perricone, G | 1 |
| Vinci, M | 1 |
| Pungolino, E | 1 |
| Lavu, S | 1 |
| Tefferi, A | 8 |
| Philipponnet, C | 1 |
| Ronco, P | 1 |
| Aniort, J | 1 |
| Kemeny, JL | 1 |
| Heng, AE | 1 |
| Tsukamoto, Y | 1 |
| Kiyasu, J | 1 |
| Tsuda, M | 1 |
| Ikeda, M | 1 |
| Shiratsuchi, M | 1 |
| Ogawa, Y | 1 |
| Yufu, Y | 1 |
| Pacilli, A | 1 |
| Mannarelli, C | 1 |
| Fanelli, T | 1 |
| Pancrazzi, A | 1 |
| Contini, E | 1 |
| Gesullo, F | 1 |
| Bartalucci, N | 1 |
| Fattori, GC | 1 |
| Paoli, C | 2 |
| Błocka-Gumowska, M | 1 |
| Holka, J | 1 |
| Ciepiela, O | 1 |
| Pugliese, N | 2 |
| Giordano, C | 1 |
| Nappi, D | 2 |
| Luciano, L | 2 |
| Cerchione, C | 2 |
| Annunziata, M | 1 |
| Casale, B | 1 |
| Crisà, E | 1 |
| Villa, MR | 1 |
| Pezzullo, L | 1 |
| Iovine, M | 1 |
| Picardi, M | 2 |
| Grimaldi, F | 1 |
| Pane, F | 3 |
| Martinelli, V | 3 |
| Andriani, A | 1 |
| Elli, E | 1 |
| Trapè, G | 1 |
| Villivà, N | 1 |
| Fianchi, L | 1 |
| Di Veroli, A | 2 |
| Niscola, P | 1 |
| Centra, A | 1 |
| Anaclerico, B | 1 |
| Montanaro, G | 1 |
| Martini, V | 1 |
| Aroldi, A | 1 |
| Carmosino, I | 1 |
| Voso, MT | 1 |
| Breccia, M | 2 |
| Montanaro, M | 1 |
| Foà, R | 2 |
| Latagliata, R | 2 |
| Ferrari, A | 1 |
| Carobbio, A | 3 |
| Masciulli, A | 2 |
| Ghirardi, A | 2 |
| Finazzi, G | 4 |
| Vianelli, N | 1 |
| Betti, S | 1 |
| Delaini, F | 1 |
| Bonifacio, M | 2 |
| Scaffidi, L | 1 |
| Patriarca, A | 1 |
| Stephenson, C | 1 |
| Elli, EM | 1 |
| Palova, M | 1 |
| Bertolotti, L | 1 |
| Erez, D | 1 |
| Lunghi, F | 1 |
| Beggiato, E | 1 |
| Carli, G | 1 |
| Cacciola, R | 1 |
| McMullin, MF | 1 |
| Tieghi, A | 1 |
| Recasens, V | 1 |
| Marchetti, M | 2 |
| Rossi, E | 1 |
| Tiribelli, M | 1 |
| Scalzulli, E | 1 |
| Martino, B | 1 |
| Caocci, G | 1 |
| Binotto, G | 1 |
| Cavo, M | 1 |
| Besses, C | 1 |
| Ruella, M | 1 |
| Risso, A | 1 |
| Buttiglieri, S | 1 |
| Spatola, T | 1 |
| Sivera, P | 1 |
| Ricca, I | 1 |
| Tarella, C | 1 |
| Rambaldi, A | 1 |
| Pecci, A | 2 |
| Croci, G | 1 |
| Balduini, CL | 1 |
| Boveri, E | 1 |
| Fu, R | 1 |
| Zhang, L | 1 |
| Yang, R | 1 |
| Tiziana Storlazzi, C | 1 |
| Pieri, L | 1 |
| Daniele, G | 1 |
| Lasho, T | 1 |
| de Unamuno-Bustos, B | 1 |
| Ballester-Sánchez, R | 1 |
| Sabater Marco, V | 1 |
| Vilata-Corell, JJ | 1 |
| Shimoda, K | 2 |
| Takenaka, K | 2 |
| Kitanaka, A | 1 |
| Akashi, K | 2 |
| Matthews, AG | 1 |
| Wylie, G | 1 |
| Riley, CH | 2 |
| Hansen, M | 1 |
| Brimnes, MK | 2 |
| Bjerrum, OW | 3 |
| Straten, PT | 2 |
| Svane, IM | 2 |
| Jensen, MK | 2 |
| Hultcrantz, M | 1 |
| Derolf, ÅR | 1 |
| Stein, BL | 2 |
| Moliterno, AR | 1 |
| Tiu, RV | 1 |
| Yoshimoto, G | 1 |
| Miyamoto, T | 1 |
| Shirane, S | 1 |
| Araki, M | 1 |
| Morishita, S | 1 |
| Edahiro, Y | 1 |
| Sunami, Y | 1 |
| Hironaka, Y | 1 |
| Noguchi, M | 1 |
| Koike, M | 1 |
| Sato, E | 1 |
| Ohsaka, A | 1 |
| Komatsu, N | 1 |
| Arcasoy, M | 1 |
| Nguyen, MH | 1 |
| Shah, N | 1 |
| Moliterno, A | 1 |
| Jamieson, C | 1 |
| Pollyea, DA | 1 |
| Scott, B | 1 |
| Wadleigh, M | 1 |
| Levine, R | 1 |
| Komrokji, R | 1 |
| Klisovic, R | 1 |
| Gundabolu, K | 1 |
| Kropf, P | 1 |
| Wetzler, M | 2 |
| Oh, ST | 1 |
| Ribeiro, R | 1 |
| Paschal, R | 1 |
| Mohan, S | 1 |
| Podoltsev, N | 1 |
| Prchal, J | 1 |
| Talpaz, M | 1 |
| Snyder, D | 1 |
| Mesa, RA | 2 |
| Aylı, M | 1 |
| Özcan, M | 1 |
| Cengiz Seval, G | 1 |
| Nazha, A | 1 |
| Soyer, N | 1 |
| Haznedaroğlu, İC | 1 |
| Cömert, M | 1 |
| Çekdemir, D | 1 |
| Yılmaz, M | 1 |
| Ünal, A | 1 |
| Çağlıyan, G | 1 |
| Bilgir, O | 1 |
| İlhan, O | 1 |
| Özdemirkıran, F | 1 |
| Kaya, E | 1 |
| Şahin, F | 1 |
| Vural, F | 1 |
| Saydam, G | 1 |
| Lim, Y | 1 |
| Uchida, N | 1 |
| Shimomura, T | 1 |
| Nagafuji, K | 1 |
| Kondo, T | 1 |
| Shibayama, H | 1 |
| Mori, T | 1 |
| Usuki, K | 1 |
| Azuma, T | 1 |
| Tsutsumi, Y | 1 |
| Tanaka, J | 1 |
| Dairaku, H | 1 |
| Matsuo, K | 1 |
| Ozawa, K | 1 |
| Kurokawa, M | 1 |
| Arai, S | 1 |
| Peluso, I | 1 |
| Pareto, AE | 1 |
| Kozielewicz, D | 1 |
| Smukalska, E | 1 |
| Dybowska, D | 1 |
| Huynh, MQ | 1 |
| Barth, P | 1 |
| Sohlbach, K | 1 |
| Neubauer, A | 1 |
| Görg, C | 1 |
| Campbell, PJ | 3 |
| Bareford, D | 3 |
| Erber, WN | 2 |
| Wilkins, BS | 3 |
| Wright, P | 1 |
| Buck, G | 3 |
| Wheatley, K | 3 |
| Harrison, CN | 4 |
| Green, AR | 4 |
| Lukina, EA | 1 |
| Sysoeva, EP | 1 |
| Kitsenko, EA | 1 |
| Varlamova, EIu | 1 |
| Inozemtseva, MV | 1 |
| Semenova, EA | 2 |
| Nadinskaia, MIu | 1 |
| Ivashkin, VT | 1 |
| Barosi, G | 2 |
| Birgegard, G | 1 |
| Harrison, C | 2 |
| Hasselbalch, H | 3 |
| Kiladijan, JJ | 1 |
| Lengfelder, E | 1 |
| Mesa, R | 1 |
| Mc Mullin, MF | 1 |
| Reilly, JT | 3 |
| Nikolaidis, I | 1 |
| Makrilia, N | 1 |
| Xyla, V | 1 |
| Dilana, K | 1 |
| Stathopoulos, D | 1 |
| Meletis, I | 1 |
| Syrigos, K | 1 |
| Beer, PA | 1 |
| Martínez-Trillos, A | 1 |
| Gaya, A | 1 |
| Calvo, X | 1 |
| Díaz-Beyá, M | 1 |
| Koren-Michowitz, M | 1 |
| Landman, J | 1 |
| Cohen, Y | 1 |
| Rahimi-Levene, N | 1 |
| Salomon, O | 1 |
| Michael, M | 1 |
| Amariglio, N | 1 |
| Nagler, A | 1 |
| Zappala, TM | 1 |
| Rodins, K | 1 |
| Muir, J | 1 |
| Vatutin, NT | 1 |
| Taradin, GG | 1 |
| Bakhteeva, TD | 1 |
| Kalinkina, NV | 1 |
| Skliannaia, EV | 1 |
| Kvasnicka, HM | 11 |
| Thiele, J | 11 |
| Schmitt-Graeff, A | 10 |
| Diehl, V | 9 |
| Niederle, N | 4 |
| Schaefer, HE | 6 |
| Zweegman, S | 1 |
| van der Valk, P | 1 |
| Jonkhoff, AR | 1 |
| Buhr, T | 1 |
| Büsche, G | 1 |
| Choritz, H | 1 |
| Länger, F | 1 |
| Kreipe, H | 1 |
| Jacob, SE | 1 |
| Lodha, R | 1 |
| Cohen, JJ | 1 |
| Romanelli, P | 1 |
| Kirsner, RS | 1 |
| Schwonzen, M | 1 |
| Spangenberger, H | 1 |
| Spengler, M | 1 |
| Nielsen, I | 1 |
| Jensen, BA | 1 |
| Clausen, NT | 1 |
| Hansen, PB | 1 |
| Birgens, H | 1 |
| Therkildsen, MH | 1 |
| Ralfkiaer, E | 1 |
| Wong, CC | 1 |
| Brown, D | 1 |
| Howling, SJ | 1 |
| Parker, NE | 1 |
| Schmitt-Gräff, A | 1 |
| Hülsemann, R | 1 |
| Bastie, JN | 1 |
| Garcia, I | 1 |
| Terré, C | 1 |
| Cross, NC | 1 |
| Mahon, FX | 1 |
| Castaigne, S | 1 |
| Rukavitsyn, OA | 1 |
| Pop, VP | 1 |
| Seriakov, AP | 1 |
| East, CL | 2 |
| van der Walt, JD | 1 |
| Grigg, AP | 1 |
| Revell, P | 1 |
| Woodcock, BE | 1 |
| Boula, A | 1 |
| Mantadakis, E | 1 |
| Xilouri, I | 1 |
| Foudoulakis, A | 1 |
| Samonis, G | 1 |
| Wakita, S | 1 |
| Yamaguchi, H | 1 |
| Okabe, M | 1 |
| Takeuchi, J | 1 |
| Tamai, H | 1 |
| Nakamura, K | 1 |
| Tajika, K | 1 |
| Inokuchi, K | 1 |
| Dan, K | 1 |
| Tanaka, Y | 1 |
| Nagai, Y | 1 |
| Mori, M | 1 |
| Fujita, H | 1 |
| Togami, K | 1 |
| Kurata, M | 1 |
| Matsushita, A | 1 |
| Maeda, A | 1 |
| Nagai, K | 1 |
| Tanaka, K | 1 |
| Takahashi, T | 1 |
| Tutaeva, V | 1 |
| Misurin, AV | 1 |
| Michiels, JJ | 1 |
| Rozenberg, JM | 1 |
| Sokolova, MA | 1 |
| Ivanova, VL | 1 |
| Kolosheinova, TI | 1 |
| Manakova, TE | 1 |
| Levina, AA | 1 |
| Khoroshko, ND | 1 |
| Paul, B | 1 |
| Retter, A | 1 |
| Radia, DH | 1 |
| Domysławska, I | 1 |
| Ciołkiewicz, M | 1 |
| Kowal-Bielecka, O | 1 |
| Lewszuk, A | 1 |
| Klimiuk, PA | 1 |
| Sierakowski, S | 1 |
| Sirhan, S | 1 |
| Lasho, TL | 1 |
| Hanson, CA | 1 |
| Pardanani, A | 1 |
| Mey, U | 1 |
| Gilbert, HS | 2 |
| Ginsberg, H | 1 |
| Fagerstrom, R | 1 |
| Brown, WV | 1 |
| Nakahata, J | 1 |
| Takahashi, M | 1 |
| Fuse, I | 1 |
| Nakamori, Y | 1 |
| Nomoto, N | 1 |
| Saitoh, H | 1 |
| Tatewaki, W | 1 |
| Imanari, A | 1 |
| Takeshige, T | 1 |
| Koike, T | 1 |
| Starmans-Kool, MJ | 1 |
| Fickers, MM | 1 |
| Pannebakker, MA | 1 |
| Hirayama, Y | 1 |
| Koda, K | 1 |
| Matsumoto, S | 1 |
| Takayanagi, M | 1 |
| Ezoe, A | 1 |
| Nobuoka, A | 1 |
| Nakazawa, O | 1 |
| Najean, Y | 4 |
| Rain, JD | 3 |
| Toubert, ME | 1 |
| Nguyen, TV | 1 |
| Margolis, DJ | 1 |
| Tura, S | 1 |
| Knobel, B | 1 |
| Melamud, E | 1 |
| Virag, I | 1 |
| Meytes, D | 1 |
| Nand, S | 1 |
| Stock, W | 1 |
| Godwin, J | 1 |
| Fisher, SG | 1 |
| Dresch, C | 1 |
| Goguel, A | 1 |
| Lejeune, F | 1 |
| Echard, M | 1 |
| Grange, MJ | 1 |
| Jowitt, SN | 1 |
| Burke, DK | 1 |
| Leggat, HM | 1 |
| Lewis, PS | 1 |
| Cryer, RJ | 1 |
| Engström, KG | 1 |
| Löfvenberg, E | 3 |
| Batlle, M | 1 |
| Fernández-Avilés, F | 1 |
| Ribera, JM | 1 |
| Millá, F | 1 |
| Granada, I | 1 |
| Gómez Espuch, J | 1 |
| Navarro, JT | 1 |
| Feliu, E | 1 |
| Silverstein, MN | 1 |
| Spohr, M | 1 |
| Zankovich, R | 5 |
| Leder, LD | 4 |
| Randi, ML | 1 |
| Rossi, C | 1 |
| Fabris, F | 1 |
| Girolami, A | 1 |
| Bundschuh, S | 1 |
| Biermann, T | 1 |
| Roessler, G | 1 |
| Wasmus, M | 1 |
| Tanaka, M | 1 |
| Kanamori, H | 1 |
| Yamaji, S | 1 |
| Mishima, A | 1 |
| Yamazaki, E | 1 |
| Taguchi, J | 1 |
| Aoba, M | 1 |
| Fujisawa, S | 1 |
| Mohri, H | 1 |
| Ishigatsubo, Y | 1 |
| Viarengo, G | 1 |
| Rosti, V | 1 |
| Piaggio, G | 1 |
| Frassoni, F | 1 |
| Goekce, D | 1 |
| Stamatopoulos, K | 1 |
| Yataganas, X | 1 |
| Papadaki, T | 1 |
| Paterakis, G | 1 |
| Naqvi, T | 1 |
| Baumann, MA | 1 |
| Friedhoff, FW | 1 |
| Atamer, MA | 1 |
| Thelmo, WL | 1 |
| Kennedy, BJ | 1 |
| Smith, LR | 1 |
| Goltz, RW | 1 |
| Voss, A | 1 |
| Schmidt, K | 1 |
| Junker, P | 1 |
| Weinstein, IM | 1 |
| Manoharan, A | 1 |
| Legrand, M | 1 |
| Poirier, O | 1 |
| Senechal, A | 1 |
| Arrago, JP | 1 |
| Schofield, JK | 1 |
| Shun, JL | 1 |
| Cerio, R | 1 |
| Grice, K | 1 |
| Wahlin, A | 2 |
| Roos, G | 1 |
| Ost, A | 1 |
| Alter, BP | 1 |
| Wagner, H | 1 |
| McKeough, PG | 1 |
| Desforges, J | 1 |
| Madoc-Jones, H | 1 |
| Froom, P | 1 |
| Aghai, E | 1 |
| Kinarty, A | 1 |
| Lahat, N | 1 |
| Schreibman, D | 1 |
| Brenner, B | 1 |
| Jacobs, R | 1 |
| Ben-Arieh, Y | 1 |
| Tatarsky, I | 1 |
| Alroy, G | 1 |
| Landaw, SA | 1 |
| Varon, D | 1 |
| Berrebi, A | 1 |
| Birgens, HS | 1 |
| Geisler, C | 1 |
| Hansen, NE | 1 |
| Mason, JE | 1 |
| DeVita, VT | 1 |
| Canellos, GP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients With Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy[NCT02953704] | 1,469 participants (Actual) | Observational | 2016-12-31 | Completed | |||
| French Aspirin Study in Essential Thrombocythemia: an Open and Randomized Study[NCT02611973] | Phase 3 | 2,250 participants (Anticipated) | Interventional | 2016-03-10 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
29 reviews available for hydroxyurea and Primary Myelofibrosis
| Article | Year |
|---|---|
SOHO State of the Art Updates and Next Questions | Polycythemia Vera: Is It Time to Rethink Treatment?
Topics: Aspirin; Humans; Hydroxyurea; Janus Kinase 2; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; | 2023 |
SOHO State of the Art Updates and Next Questions | Polycythemia Vera: Is It Time to Rethink Treatment?
Topics: Aspirin; Humans; Hydroxyurea; Janus Kinase 2; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; | 2023 |
Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
Topics: Age Factors; Calreticulin; Female; Hematocrit; Humans; Hydroxyurea; Interferons; Janus Kinase 2; Mal | 2017 |
Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
Topics: Age Factors; Calreticulin; Female; Hematocrit; Humans; Hydroxyurea; Interferons; Janus Kinase 2; Mal | 2017 |
Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature.
Topics: Aged; Fatal Outcome; Humans; Hydroxyurea; Male; Prednisolone; Primary Myelofibrosis; Pyrazoles; Tube | 2018 |
Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature.
Topics: Aged; Fatal Outcome; Humans; Hydroxyurea; Male; Prednisolone; Primary Myelofibrosis; Pyrazoles; Tube | 2018 |
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis.
Topics: Hemorrhage; Humans; Hydroxyurea; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Risk Factors; | 2019 |
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis.
Topics: Hemorrhage; Humans; Hydroxyurea; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Risk Factors; | 2019 |
[Treatment of essential thrombocythemia].
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progress | 2013 |
[Treatment of essential thrombocythemia].
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progress | 2013 |
Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.
Topics: Adolescent; Age of Onset; Anticoagulants; Child; Child, Preschool; Clone Cells; Disease Progression; | 2013 |
Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.
Topics: Adolescent; Age of Onset; Anticoagulants; Child; Child, Preschool; Clone Cells; Disease Progression; | 2013 |
[Clinical aspects of primary myelofibrosis in Japan].
Topics: Blood Cell Count; Danazol; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Japan; Meth | 2014 |
[Clinical aspects of primary myelofibrosis in Japan].
Topics: Blood Cell Count; Danazol; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Japan; Meth | 2014 |
Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Progression; Humans; Hydroxyurea; Ja | 2014 |
Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Progression; Humans; Hydroxyurea; Ja | 2014 |
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Topics: Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cost of Illness; Disease Progression | 2014 |
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Topics: Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cost of Illness; Disease Progression | 2014 |
[Treatment strategy for myeloproliferative neoplasms].
Topics: Adrenal Cortex Hormones; Aspirin; Calreticulin; Carbamates; Clinical Trials as Topic; Drug Therapy, | 2014 |
[Treatment strategy for myeloproliferative neoplasms].
Topics: Adrenal Cortex Hormones; Aspirin; Calreticulin; Carbamates; Clinical Trials as Topic; Drug Therapy, | 2014 |
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Disease Management; Humans; Hydroxyurea; Janus Kinas | 2015 |
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Disease Management; Humans; Hydroxyurea; Janus Kinas | 2015 |
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
Topics: Antineoplastic Agents; Calreticulin; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; J | 2015 |
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
Topics: Antineoplastic Agents; Calreticulin; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; J | 2015 |
Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Topics: Busulfan; Cell Proliferation; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myeloid, Acute; Nitrile | 2016 |
Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Topics: Busulfan; Cell Proliferation; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myeloid, Acute; Nitrile | 2016 |
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.
Topics: Antineoplastic Agents; Consensus Development Conferences as Topic; Drug Resistance; Humans; Hydroxyu | 2010 |
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.
Topics: Antineoplastic Agents; Consensus Development Conferences as Topic; Drug Resistance; Humans; Hydroxyu | 2010 |
Pathogenesis and management of essential thrombocythemia.
Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyu | 2009 |
Pathogenesis and management of essential thrombocythemia.
Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyu | 2009 |
Do we know more about essential thrombocythemia because of JAK2V617F?
Topics: Female; Humans; Hydroxyurea; Janus Kinase 2; Polycythemia Vera; Pregnancy; Pregnancy Complications; | 2009 |
Do we know more about essential thrombocythemia because of JAK2V617F?
Topics: Female; Humans; Hydroxyurea; Janus Kinase 2; Polycythemia Vera; Pregnancy; Pregnancy Complications; | 2009 |
Hydroxyurea induced dermatomyositis-like eruption.
Topics: Aged; Anemia, Megaloblastic; Antineoplastic Agents; Dermatomyositis; Drug Eruptions; Female; Humans; | 2012 |
Hydroxyurea induced dermatomyositis-like eruption.
Topics: Aged; Anemia, Megaloblastic; Antineoplastic Agents; Dermatomyositis; Drug Eruptions; Female; Humans; | 2012 |
[True polycythemia: current views of pathogenesis, diagnostics and treatment].
Topics: Age Factors; Algorithms; Antineoplastic Agents; Aspirin; Benzamides; Combined Modality Therapy; Hema | 2012 |
[True polycythemia: current views of pathogenesis, diagnostics and treatment].
Topics: Age Factors; Algorithms; Antineoplastic Agents; Aspirin; Benzamides; Combined Modality Therapy; Hema | 2012 |
Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Busulfan; Ch | 2004 |
Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Busulfan; Ch | 2004 |
Myelofibrosis: biology and treatment options.
Topics: Benzamides; Chronic Disease; Darbepoetin alfa; Erythropoietin; Hematopoietic Stem Cell Transplantati | 2007 |
Myelofibrosis: biology and treatment options.
Topics: Benzamides; Chronic Disease; Darbepoetin alfa; Erythropoietin; Hematopoietic Stem Cell Transplantati | 2007 |
The management of elderly patients with myeloproliferative disorders.
Topics: Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Chronic Disease; Humans; Hydroxyure | 1993 |
The management of elderly patients with myeloproliferative disorders.
Topics: Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Chronic Disease; Humans; Hydroxyure | 1993 |
Ectopic medullary hematopoiesis as a cause of ascites in agnogenic myeloid metaplasia. Case report and review of the literature.
Topics: Anemia, Hemolytic; Ascites; Biopsy; Bone Marrow; Busulfan; Combined Modality Therapy; Coombs Test; D | 1993 |
Ectopic medullary hematopoiesis as a cause of ascites in agnogenic myeloid metaplasia. Case report and review of the literature.
Topics: Anemia, Hemolytic; Ascites; Biopsy; Bone Marrow; Busulfan; Combined Modality Therapy; Coombs Test; D | 1993 |
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
Pathogenesis and management of idiopathic myelofibrosis.
Topics: Anemia; Animals; Bone Marrow; Bone Marrow Transplantation; Cladribine; Combined Modality Therapy; Di | 1998 |
Pathogenesis and management of idiopathic myelofibrosis.
Topics: Anemia; Animals; Bone Marrow; Bone Marrow Transplantation; Cladribine; Combined Modality Therapy; Di | 1998 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
Treatment of polycythaemia vera and essential thrombocythaemia.
Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In | 1998 |
Myelofibrosis with myeloid metaplasia.
Topics: Antineoplastic Agents; Bone Marrow; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation | 2000 |
Myelofibrosis with myeloid metaplasia.
Topics: Antineoplastic Agents; Bone Marrow; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation | 2000 |
Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000.
Topics: Aged; Anemia; Aneuploidy; Angiogenesis Inhibitors; Bone Marrow Transplantation; Case Management; Com | 2001 |
Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000.
Topics: Aged; Anemia; Aneuploidy; Angiogenesis Inhibitors; Bone Marrow Transplantation; Case Management; Com | 2001 |
Myelofibrosis: response to busulfan after hydroxyurea failure.
Topics: Alkylating Agents; Antimetabolites; Busulfan; Gastrointestinal Hemorrhage; Humans; Hydroxyurea; Male | 2002 |
Myelofibrosis: response to busulfan after hydroxyurea failure.
Topics: Alkylating Agents; Antimetabolites; Busulfan; Gastrointestinal Hemorrhage; Humans; Hydroxyurea; Male | 2002 |
Idiopathic myelofibrosis: historical review, diagnosis and management.
Topics: Anemia; Bone Marrow; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Diagnosis, Di | 1991 |
Idiopathic myelofibrosis: historical review, diagnosis and management.
Topics: Anemia; Bone Marrow; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Diagnosis, Di | 1991 |
11 trials available for hydroxyurea and Primary Myelofibrosis
| Article | Year |
|---|---|
Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population-based cohort study in Sweden and Norway.
Topics: Aged; Busulfan; Danazol; Disease-Free Survival; Female; Follow-Up Studies; Glucocorticoids; Humans; | 2019 |
Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population-based cohort study in Sweden and Norway.
Topics: Aged; Busulfan; Danazol; Disease-Free Survival; Female; Follow-Up Studies; Glucocorticoids; Humans; | 2019 |
Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Topics: Aged; Alleles; Antineoplastic Agents; Blood Cell Count; Cohort Studies; Female; Humans; Hydroxyurea; | 2021 |
Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Topics: Aged; Alleles; Antineoplastic Agents; Blood Cell Count; Cohort Studies; Female; Humans; Hydroxyurea; | 2021 |
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.
Topics: Biomarkers; Bone Marrow; Hemoglobins; Hemorrhage; Humans; Hydroxyurea; Leukocyte Count; Platelet Agg | 2009 |
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.
Topics: Biomarkers; Bone Marrow; Hemoglobins; Hemorrhage; Humans; Hydroxyurea; Leukocyte Count; Platelet Agg | 2009 |
Impact of bone marrow morphology on multivariate risk classification in chronic myelogenous leukemia.
Topics: Bone Marrow; Erythroid Precursor Cells; Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon- | 2003 |
Impact of bone marrow morphology on multivariate risk classification in chronic myelogenous leukemia.
Topics: Bone Marrow; Erythroid Precursor Cells; Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon- | 2003 |
Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; | 2003 |
Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; | 2003 |
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; F | 2005 |
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; F | 2005 |
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.
Topics: Adult; Antineoplastic Agents; Aspirin; Biopsy; Blood Cell Count; Drug Therapy, Combination; Hematolo | 2008 |
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.
Topics: Adult; Antineoplastic Agents; Aspirin; Biopsy; Blood Cell Count; Drug Therapy, Combination; Hematolo | 2008 |
[Treatment of polycythemia with 32P with or without hydroxyurea maintenance therapy. Preliminary results in 237 elderly and high vascular risk subjects studied since 1980].
Topics: Age Factors; Aged; Carcinoma; Cardiovascular Diseases; Female; Humans; Hydroxyurea; Injections, Intr | 1993 |
[Treatment of polycythemia with 32P with or without hydroxyurea maintenance therapy. Preliminary results in 237 elderly and high vascular risk subjects studied since 1980].
Topics: Age Factors; Aged; Carcinoma; Cardiovascular Diseases; Female; Humans; Hydroxyurea; Injections, Intr | 1993 |
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Topics: Actuarial Analysis; Acute Disease; Carcinoma; Cause of Death; Disease Progression; Follow-Up Studies | 1996 |
Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group.
Topics: Actuarial Analysis; Aged; Alkylating Agents; Combined Modality Therapy; Disease Progression; Follow- | 1997 |
Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group.
Topics: Actuarial Analysis; Aged; Alkylating Agents; Combined Modality Therapy; Disease Progression; Follow- | 1997 |
Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial.
Topics: Antineoplastic Agents; Bone Marrow; Decision Trees; Female; Humans; Hydroxyurea; Interferon alpha-2; | 2001 |
Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial.
Topics: Antineoplastic Agents; Bone Marrow; Decision Trees; Female; Humans; Hydroxyurea; Interferon alpha-2; | 2001 |
101 other studies available for hydroxyurea and Primary Myelofibrosis
| Article | Year |
|---|---|
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Hydroxyurea; Incidence; Janus Kin | 2021 |
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Hydroxyurea; Incidence; Janus Kin | 2021 |
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study.
Topics: Aged; Cohort Studies; Humans; Hydroxyurea; Primary Myelofibrosis; Prospective Studies; Thrombocythem | 2022 |
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study.
Topics: Aged; Cohort Studies; Humans; Hydroxyurea; Primary Myelofibrosis; Prospective Studies; Thrombocythem | 2022 |
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Topics: Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Nitriles; Poly | 2022 |
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Topics: Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Nitriles; Poly | 2022 |
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.
Topics: Humans; Hydroxyurea; Janus Kinase Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Thrombocythe | 2022 |
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.
Topics: Humans; Hydroxyurea; Janus Kinase Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Thrombocythe | 2022 |
Differences between aquagenic and non-aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients.
Topics: Humans; Hydroxyurea; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis; Pruritu | 2023 |
Differences between aquagenic and non-aquagenic pruritus in myeloproliferative neoplasms: An observational study of 500 patients.
Topics: Humans; Hydroxyurea; Myeloproliferative Disorders; Polycythemia Vera; Primary Myelofibrosis; Pruritu | 2023 |
Detection of primary myelofibrosis in blood serum via Raman spectroscopy assisted by machine learning approaches; correlation with clinical diagnosis.
Topics: Biomarkers; Humans; Hydroxyurea; Polycythemia Vera; Primary Myelofibrosis; Serum; Spectrum Analysis, | 2023 |
Detection of primary myelofibrosis in blood serum via Raman spectroscopy assisted by machine learning approaches; correlation with clinical diagnosis.
Topics: Biomarkers; Humans; Hydroxyurea; Polycythemia Vera; Primary Myelofibrosis; Serum; Spectrum Analysis, | 2023 |
Moving toward disease modification in polycythemia vera.
Topics: Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Leukemia, Myeloid, Acute; Polycythemia Vera; | 2023 |
Moving toward disease modification in polycythemia vera.
Topics: Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Leukemia, Myeloid, Acute; Polycythemia Vera; | 2023 |
Complete resolution of primary myelofibrosis in an infant with steroids and hydroxyurea.
Topics: Humans; Hydroxyurea; Infant; Primary Myelofibrosis; Remission, Spontaneous; Steroids; Thrombocytopen | 2023 |
Complete resolution of primary myelofibrosis in an infant with steroids and hydroxyurea.
Topics: Humans; Hydroxyurea; Infant; Primary Myelofibrosis; Remission, Spontaneous; Steroids; Thrombocytopen | 2023 |
Hydroxyurea-induced Tooth Discoloration
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Hydroxyurea; Male; Primary Myelofibrosis; Tooth Di | 2020 |
Hydroxyurea-induced Tooth Discoloration
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Hydroxyurea; Male; Primary Myelofibrosis; Tooth Di | 2020 |
Development of myelofibrosis and acute monocytic leukemia in a patient with hereditary spherocytosis: A case report.
Topics: Biopsy; Follow-Up Studies; Humans; Hydroxyurea; Leukemia, Monocytic, Acute; Male; Middle Aged; Prima | 2019 |
Development of myelofibrosis and acute monocytic leukemia in a patient with hereditary spherocytosis: A case report.
Topics: Biopsy; Follow-Up Studies; Humans; Hydroxyurea; Leukemia, Monocytic, Acute; Male; Middle Aged; Prima | 2019 |
Transudative Pleural Effusion Associated with Extramedullary Hematopoiesis.
Topics: Aged; Hematologic Diseases; Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Male; Pleural Effusi | 2021 |
Transudative Pleural Effusion Associated with Extramedullary Hematopoiesis.
Topics: Aged; Hematologic Diseases; Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Male; Pleural Effusi | 2021 |
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bone Marrow; Calreticulin; Dexamethas | 2021 |
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bone Marrow; Calreticulin; Dexamethas | 2021 |
Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
Topics: Adolescent; Adult; Antineoplastic Agents; Aspirin; Child; Female; Fibrinolytic Agents; Follow-Up Stu | 2021 |
Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
Topics: Adolescent; Adult; Antineoplastic Agents; Aspirin; Child; Female; Fibrinolytic Agents; Follow-Up Stu | 2021 |
IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia.
Topics: Biomarkers; Humans; Hydroxyurea; Interferon Regulatory Factors; Janus Kinase 2; Leukemia, Myeloid, A | 2022 |
IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia.
Topics: Biomarkers; Humans; Hydroxyurea; Interferon Regulatory Factors; Janus Kinase 2; Leukemia, Myeloid, A | 2022 |
Occult hepatitis B infection reactivation after ruxolitinib therapy.
Topics: Aged; Antiviral Agents; Drug Resistance; Enzyme Inhibitors; Guanine; Hepatitis B, Chronic; Humans; H | 2017 |
Occult hepatitis B infection reactivation after ruxolitinib therapy.
Topics: Aged; Antiviral Agents; Drug Resistance; Enzyme Inhibitors; Guanine; Hepatitis B, Chronic; Humans; H | 2017 |
Cardiac tamponade in myelofibrosis: A Mayo clinic series of nine consecutive cases.
Topics: Aged; Aged, 80 and over; Cardiac Tamponade; Female; Hematopoiesis, Extramedullary; Humans; Hydroxyur | 2017 |
Cardiac tamponade in myelofibrosis: A Mayo clinic series of nine consecutive cases.
Topics: Aged; Aged, 80 and over; Cardiac Tamponade; Female; Hematopoiesis, Extramedullary; Humans; Hydroxyur | 2017 |
Membranous Nephropathy and Intrarenal Extramedullary Hematopoiesis in a Patient With Myelofibrosis.
Topics: Acute Kidney Injury; Antineoplastic Agents; Edema; Glomerulonephritis, Membranous; Hematopoiesis, Ex | 2017 |
Membranous Nephropathy and Intrarenal Extramedullary Hematopoiesis in a Patient With Myelofibrosis.
Topics: Acute Kidney Injury; Antineoplastic Agents; Edema; Glomerulonephritis, Membranous; Hematopoiesis, Ex | 2017 |
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans; | 2019 |
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; DNA Mutational Analysis; Female; Follow-Up Studies; Huma | 2018 |
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; DNA Mutational Analysis; Female; Follow-Up Studies; Huma | 2018 |
Hypersegmentation of Granulocytes and Monocytes in a Patient with Primary Myelofibrosis Treated with Hydroxycarbamide
Topics: Granulocytes; Humans; Hydroxyurea; Male; Middle Aged; Monocytes; Primary Myelofibrosis | 2019 |
Hypersegmentation of Granulocytes and Monocytes in a Patient with Primary Myelofibrosis Treated with Hydroxycarbamide
Topics: Granulocytes; Humans; Hydroxyurea; Male; Middle Aged; Monocytes; Primary Myelofibrosis | 2019 |
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Drug Therapy, Combination; Female | 2019 |
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Drug Therapy, Combination; Female | 2019 |
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Female; Humans; Hydroxyurea; Leuke | 2019 |
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Female; Humans; Hydroxyurea; Leuke | 2019 |
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.
Topics: Antineoplastic Agents; Case-Control Studies; Humans; Hydroxyurea; Neoplasms, Second Primary; Nitrile | 2019 |
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.
Topics: Antineoplastic Agents; Case-Control Studies; Humans; Hydroxyurea; Neoplasms, Second Primary; Nitrile | 2019 |
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis.
Topics: Aged; Aged, 80 and over; Blood Platelets; Cell Count; Cell Proliferation; Drug Administration Schedu | 2019 |
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis.
Topics: Aged; Aged, 80 and over; Blood Platelets; Cell Count; Cell Proliferation; Drug Administration Schedu | 2019 |
Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Child; Child, Preschool; Clone Cells; Female | 2013 |
Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Child; Child, Preschool; Clone Cells; Female | 2013 |
Cutaneous involvement by post-polycythemia vera myelofibrosis.
Topics: Aged; Aspirin; Biopsy; Cell Lineage; Disease Progression; Drug Therapy, Combination; Fibrosis; Hemat | 2014 |
Cutaneous involvement by post-polycythemia vera myelofibrosis.
Topics: Aged; Aspirin; Biopsy; Cell Lineage; Disease Progression; Drug Therapy, Combination; Fibrosis; Hemat | 2014 |
Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 6; Combined Modality Ther | 2014 |
Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 6; Combined Modality Ther | 2014 |
Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.
Topics: Chronic Disease; Comorbidity; Humans; Hydroxyurea; Inflammation; Interferon alpha-2; Interferon-alph | 2014 |
Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.
Topics: Chronic Disease; Comorbidity; Humans; Hydroxyurea; Inflammation; Interferon alpha-2; Interferon-alph | 2014 |
Dermatomyositis-like eruption associated with hydroxyurea therapy: a premalignant condition?
Topics: Aged; Dermatomyositis; Diagnosis, Differential; Drug Eruptions; Drug Substitution; Erythema; Female; | 2014 |
Dermatomyositis-like eruption associated with hydroxyurea therapy: a premalignant condition?
Topics: Aged; Dermatomyositis; Diagnosis, Differential; Drug Eruptions; Drug Substitution; Erythema; Female; | 2014 |
Hydroxycarbamide-induced cutaneous ulceration with a difference.
Topics: Diagnosis, Differential; Drug Eruptions; Female; Hematinics; Humans; Hydroxyurea; Middle Aged; Prima | 2014 |
Hydroxycarbamide-induced cutaneous ulceration with a difference.
Topics: Diagnosis, Differential; Drug Eruptions; Female; Hematinics; Humans; Hydroxyurea; Middle Aged; Prima | 2014 |
Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; CD56 Antigen; Female; G | 2015 |
Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; CD56 Antigen; Female; G | 2015 |
Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
Topics: Alleles; Bone Marrow; Disease Progression; Humans; Hydroxyurea; Janus Kinase 2; Mutation; Polycythem | 2015 |
Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
Topics: Alleles; Bone Marrow; Disease Progression; Humans; Hydroxyurea; Janus Kinase 2; Mutation; Polycythem | 2015 |
Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.
Topics: Aged; Aspergillosis; Blood Transfusion; Danazol; Disease Progression; Drug Resistance; Fatal Outcome | 2015 |
Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.
Topics: Aged; Aspergillosis; Blood Transfusion; Danazol; Disease Progression; Drug Resistance; Fatal Outcome | 2015 |
Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Chronic Disease; Fe | 2017 |
Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Chronic Disease; Fe | 2017 |
Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Databases, Factual; Drug Prescr | 2016 |
Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Databases, Factual; Drug Prescr | 2016 |
Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan.
Topics: Adult; Androgens; Antineoplastic Agents; Cohort Studies; Erythrocyte Transfusion; Female; Hematopoie | 2017 |
Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan.
Topics: Adult; Androgens; Antineoplastic Agents; Cohort Studies; Erythrocyte Transfusion; Female; Hematopoie | 2017 |
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Erythropoietin; Humans; Hydroxyurea; Interferon-alph | 2017 |
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Topics: Aspirin; Calreticulin; Diagnosis, Differential; Erythropoietin; Humans; Hydroxyurea; Interferon-alph | 2017 |
Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cachexia; Drug Administration Sch | 2017 |
Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cachexia; Drug Administration Sch | 2017 |
[Budd-Chiari syndrome--from diagnosis to treatment--case reports].
Topics: Adult; Anticoagulants; Budd-Chiari Syndrome; Female; Humans; Hydroxyurea; Polycythemia; Primary Myel | 2008 |
[Budd-Chiari syndrome--from diagnosis to treatment--case reports].
Topics: Adult; Anticoagulants; Budd-Chiari Syndrome; Female; Humans; Hydroxyurea; Polycythemia; Primary Myel | 2008 |
B-mode ultrasound and contrast-enhanced ultrasound pattern of focal extramedullary hematopoiesis of the spleen in a patient with myeloproliferative disease.
Topics: Aged; Biopsy, Needle; Bloodletting; Bone Marrow; Contrast Media; Diagnosis, Differential; Follow-Up | 2009 |
B-mode ultrasound and contrast-enhanced ultrasound pattern of focal extramedullary hematopoiesis of the spleen in a patient with myeloproliferative disease.
Topics: Aged; Biopsy, Needle; Bloodletting; Bone Marrow; Contrast Media; Diagnosis, Differential; Follow-Up | 2009 |
[Syndrome of extrahepatic portal hypertension and chronic abdominal ischemia in patient with subleukemic myelosis and congenital immunodeficiency].
Topics: Abdomen; Adult; Anticoagulants; Antineoplastic Agents; Chronic Disease; Female; Humans; Hydroxyurea; | 2009 |
[Syndrome of extrahepatic portal hypertension and chronic abdominal ischemia in patient with subleukemic myelosis and congenital immunodeficiency].
Topics: Abdomen; Adult; Anticoagulants; Antineoplastic Agents; Chronic Disease; Female; Humans; Hydroxyurea; | 2009 |
Bevacizumab may be active in myelofibrosis.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizuma | 2010 |
Bevacizumab may be active in myelofibrosis.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizuma | 2010 |
Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antisickling Agents; Bone and Bones; Female; Humans; Hydroxy | 2010 |
Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antisickling Agents; Bone and Bones; Female; Humans; Hydroxy | 2010 |
JAK inhibition in myelofibrosis.
Topics: Humans; Hydroxyurea; Janus Kinase 1; Janus Kinase 2; Mutation; Nitriles; Palliative Care; Primary My | 2010 |
JAK inhibition in myelofibrosis.
Topics: Humans; Hydroxyurea; Janus Kinase 1; Janus Kinase 2; Mutation; Nitriles; Palliative Care; Primary My | 2010 |
Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α.
Topics: Adult; Aged; Antineoplastic Agents; Female; Forkhead Transcription Factors; Humans; Hydroxyurea; Int | 2011 |
Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α.
Topics: Adult; Aged; Antineoplastic Agents; Female; Forkhead Transcription Factors; Humans; Hydroxyurea; Int | 2011 |
JAK2V617F allele burden is associated with transformation to myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Cell Transformation, Neoplastic; Female; Humans; Hydroxyure | 2012 |
JAK2V617F allele burden is associated with transformation to myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Cell Transformation, Neoplastic; Female; Humans; Hydroxyure | 2012 |
How I treat polycythemia vera.
Topics: Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Janus Kinase 2; Janus Kinases; Ma | 2012 |
How I treat polycythemia vera.
Topics: Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Janus Kinase 2; Janus Kinases; Ma | 2012 |
[Diagnostic image (117). A man with frequent blood transfusion and blister on his fingers. A form of porpheria cutanea tarda caused by excess iron].
Topics: Aged; Blister; Diagnosis, Differential; Enzyme Inhibitors; Humans; Hydroxyurea; Iron Chelating Agent | 2002 |
[Diagnostic image (117). A man with frequent blood transfusion and blister on his fingers. A form of porpheria cutanea tarda caused by excess iron].
Topics: Aged; Blister; Diagnosis, Differential; Enzyme Inhibitors; Humans; Hydroxyurea; Iron Chelating Agent | 2002 |
Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Chroni | 2003 |
Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Chroni | 2003 |
Paraneoplastic eosinophilic fasciitis: a case report.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Eosinophilia; Fasciitis; Female; Humans; Hydroxyure | 2003 |
Paraneoplastic eosinophilic fasciitis: a case report.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Eosinophilia; Fasciitis; Female; Humans; Hydroxyure | 2003 |
Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients.
Topics: Biopsy; Bone Marrow; Busulfan; Disease Progression; Follow-Up Studies; Humans; Hydroxyurea; Interfer | 2003 |
Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients.
Topics: Biopsy; Bone Marrow; Busulfan; Disease Progression; Follow-Up Studies; Humans; Hydroxyurea; Interfer | 2003 |
[Hydroxyurea-induced pneumonitis].
Topics: Antineoplastic Agents; Diagnosis, Differential; Humans; Hydroxyurea; Male; Middle Aged; Pneumonia; P | 2003 |
[Hydroxyurea-induced pneumonitis].
Topics: Antineoplastic Agents; Diagnosis, Differential; Humans; Hydroxyurea; Male; Middle Aged; Pneumonia; P | 2003 |
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Topics: Acute Disease; Alkylating Agents; Busulfan; Chronic Disease; Drug Therapy, Combination; Female; Huma | 2003 |
Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Topics: Acute Disease; Alkylating Agents; Busulfan; Chronic Disease; Drug Therapy, Combination; Female; Huma | 2003 |
Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis.
Topics: Aged; Antineoplastic Agents; Bone Marrow; Busulfan; Female; Hematopoiesis; Humans; Hydroxyurea; Inte | 2003 |
Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis.
Topics: Aged; Antineoplastic Agents; Bone Marrow; Busulfan; Female; Hematopoiesis; Humans; Hydroxyurea; Inte | 2003 |
Hydroxyurea-induced pneumonitis in a patient with chronic idiopathic myelofibrosis after prolonged drug exposure.
Topics: Diagnosis, Differential; Humans; Hydroxyurea; Male; Middle Aged; Pneumonia; Primary Myelofibrosis | 2003 |
Hydroxyurea-induced pneumonitis in a patient with chronic idiopathic myelofibrosis after prolonged drug exposure.
Topics: Diagnosis, Differential; Humans; Hydroxyurea; Male; Middle Aged; Pneumonia; Primary Myelofibrosis | 2003 |
Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene.
Topics: Benzamides; Biomarkers; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 5; Disease Progression | 2004 |
Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene.
Topics: Benzamides; Biomarkers; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 5; Disease Progression | 2004 |
[Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; | 2004 |
[Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; | 2004 |
When and how to treat essential thrombocythemia.
Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia | 2005 |
When and how to treat essential thrombocythemia.
Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia | 2005 |
Agnogenic myeloid metaplasia with pulmonary hematopoiesis.
Topics: Aged; Fatal Outcome; Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Male; Primary Myelofibrosis | 2005 |
Agnogenic myeloid metaplasia with pulmonary hematopoiesis.
Topics: Aged; Fatal Outcome; Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Male; Primary Myelofibrosis | 2005 |
Effects of anagrelide on megakaryopoiesis and platelet production.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Differentiation; Drug Evaluation; Human | 2006 |
Effects of anagrelide on megakaryopoiesis and platelet production.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Differentiation; Drug Evaluation; Human | 2006 |
[Low dose whole lung irradiation for intractable pleural effusion due to idiopathic myelofibrosis].
Topics: Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Lung; Male; Middle Aged; Pleural Effusion; Prima | 2006 |
[Low dose whole lung irradiation for intractable pleural effusion due to idiopathic myelofibrosis].
Topics: Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Lung; Male; Middle Aged; Pleural Effusion; Prima | 2006 |
Multiple granulocytic sarcomas in essential thrombocythemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Chromosome Deletion; Chromosomes, | 2006 |
Multiple granulocytic sarcomas in essential thrombocythemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Chromosome Deletion; Chromosomes, | 2006 |
Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Topics: Diagnosis, Differential; GPI-Linked Proteins; Humans; Hydroxyurea; Interferon-alpha; Isoantigens; Ja | 2007 |
Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Topics: Diagnosis, Differential; GPI-Linked Proteins; Humans; Hydroxyurea; Interferon-alpha; Isoantigens; Ja | 2007 |
Improvement of fibrosis in a patient with chronic myeloproliferative disease.
Topics: Adult; Biopsy; Follow-Up Studies; Humans; Hydroxyurea; Interferon-alpha; Male; Nucleic Acid Synthesi | 2007 |
Improvement of fibrosis in a patient with chronic myeloproliferative disease.
Topics: Adult; Biopsy; Follow-Up Studies; Humans; Hydroxyurea; Interferon-alpha; Male; Nucleic Acid Synthesi | 2007 |
[Coexistence of scleroderma-like syndrome and idiopathic myelofibrosis in a 54-year-old female patient: case report].
Topics: Antineoplastic Agents; Azathioprine; Female; Glucocorticoids; Humans; Hydroxyurea; Immunosuppressive | 2007 |
[Coexistence of scleroderma-like syndrome and idiopathic myelofibrosis in a 54-year-old female patient: case report].
Topics: Antineoplastic Agents; Azathioprine; Female; Glucocorticoids; Humans; Hydroxyurea; Immunosuppressive | 2007 |
The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
Topics: Adult; Age Factors; Aged; Alleles; Cohort Studies; DNA Mutational Analysis; Drug Resistance; Female; | 2008 |
The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
Topics: Adult; Age Factors; Aged; Alleles; Cohort Studies; DNA Mutational Analysis; Drug Resistance; Female; | 2008 |
[Therapy of chronic myeloid leukemia].
Topics: Busulfan; Chromosomes, Human, 21-22 and Y; Drug Administration Schedule; Humans; Hydroxyurea; Leukem | 1981 |
[Therapy of chronic myeloid leukemia].
Topics: Busulfan; Chromosomes, Human, 21-22 and Y; Drug Administration Schedule; Humans; Hydroxyurea; Leukem | 1981 |
Characterization of hypocholesterolemia in myeloproliferative disease. Relation to disease manifestations and activity.
Topics: Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxyurea; Lipoproteins, HD | 1981 |
Characterization of hypocholesterolemia in myeloproliferative disease. Relation to disease manifestations and activity.
Topics: Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxyurea; Lipoproteins, HD | 1981 |
Paroxysmal nocturnal hemoglobinuria with myelofibrosis: progression to acute myeloblastic leukemia.
Topics: Antigens, CD; Blood Proteins; CD55 Antigens; CD59 Antigens; Erythrocytes; Flow Cytometry; Granulocyt | 1993 |
Paroxysmal nocturnal hemoglobinuria with myelofibrosis: progression to acute myeloblastic leukemia.
Topics: Antigens, CD; Blood Proteins; CD55 Antigens; CD59 Antigens; Erythrocytes; Flow Cytometry; Granulocyt | 1993 |
An unwanted side effect of hydroxyurea in a patient with idiopathic myelofibrosis.
Topics: Aged; Fever; Humans; Hydroxyurea; Male; Primary Myelofibrosis | 1995 |
An unwanted side effect of hydroxyurea in a patient with idiopathic myelofibrosis.
Topics: Aged; Fever; Humans; Hydroxyurea; Male; Primary Myelofibrosis | 1995 |
[A case of chronic neutrophilic leukemia accompanied with severe bone marrow fibrosis which was effectively treated by hydroxyurea].
Topics: Humans; Hydroxyurea; Leukemia, Neutrophilic, Chronic; Male; Middle Aged; Primary Myelofibrosis | 1994 |
[A case of chronic neutrophilic leukemia accompanied with severe bone marrow fibrosis which was effectively treated by hydroxyurea].
Topics: Humans; Hydroxyurea; Leukemia, Neutrophilic, Chronic; Male; Middle Aged; Primary Myelofibrosis | 1994 |
Hydroxyurea and lower leg ulcers.
Topics: Aged; Female; Humans; Hydroxyurea; Leg Ulcer; Male; Middle Aged; Polycythemia Vera; Primary Myelofib | 1993 |
Hydroxyurea and lower leg ulcers.
Topics: Aged; Female; Humans; Hydroxyurea; Leg Ulcer; Male; Middle Aged; Polycythemia Vera; Primary Myelofib | 1993 |
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic; | 1996 |
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic; | 1996 |
Pleural effusion secondary to extramedullary haemopoiesis in a patient with idiopathic myelofibrosis responding to pleurodesis and hydroxyurea.
Topics: Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Male; Middle Aged; Pleural Effusion; Pleurodesis | 1997 |
Pleural effusion secondary to extramedullary haemopoiesis in a patient with idiopathic myelofibrosis responding to pleurodesis and hydroxyurea.
Topics: Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Male; Middle Aged; Pleural Effusion; Pleurodesis | 1997 |
Treatment of myeloproliferative disorders with hydroxyurea: effects on red blood cell geometry and deformability.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Cats; Cell Size; Erythrocyte Deformability; Erythr | 1998 |
Treatment of myeloproliferative disorders with hydroxyurea: effects on red blood cell geometry and deformability.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Cats; Cell Size; Erythrocyte Deformability; Erythr | 1998 |
Acute promyelocytic leukemia in a patient with idiopathic myelofibrosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hydroxyurea; Idarubicin; Leuke | 1999 |
Acute promyelocytic leukemia in a patient with idiopathic myelofibrosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hydroxyurea; Idarubicin; Leuke | 1999 |
Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study.
Topics: Adult; Antineoplastic Agents; Biopsy; Cell Division; Cohort Studies; Female; Humans; Hydroxyurea; In | 2000 |
Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study.
Topics: Adult; Antineoplastic Agents; Biopsy; Cell Division; Cohort Studies; Female; Humans; Hydroxyurea; In | 2000 |
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free | 2000 |
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free | 2000 |
Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Busulfan; Disease Pro | 2000 |
Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Busulfan; Disease Pro | 2000 |
Changing patterns of histological subgroups during therapy of Ph1+ chronic myelogenous leukaemia.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Busulfan; Granulocytes; Humans; Hydroxyurea; Interferon a | 2000 |
Changing patterns of histological subgroups during therapy of Ph1+ chronic myelogenous leukaemia.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Busulfan; Granulocytes; Humans; Hydroxyurea; Interferon a | 2000 |
Prognostic impact of bone marrow erythropoietic precursor cells and myelofibrosis at diagnosis of Ph1+ chronic myelogenous leukaemia--a multicentre study on 495 patients.
Topics: Adult; Bone Marrow; Busulfan; Erythroid Precursor Cells; Female; Humans; Hydroxyurea; Immunohistoche | 2001 |
Prognostic impact of bone marrow erythropoietic precursor cells and myelofibrosis at diagnosis of Ph1+ chronic myelogenous leukaemia--a multicentre study on 495 patients.
Topics: Adult; Bone Marrow; Busulfan; Erythroid Precursor Cells; Female; Humans; Hydroxyurea; Immunohistoche | 2001 |
Subcutaneous extramedullary hematopoiesis in a patient with secondary myelofibrosis following polycythemia vera.
Topics: Aged; Female; Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Megakaryocytes; Myeloid Cells; Pol | 2001 |
Subcutaneous extramedullary hematopoiesis in a patient with secondary myelofibrosis following polycythemia vera.
Topics: Aged; Female; Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Megakaryocytes; Myeloid Cells; Pol | 2001 |
Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Cell Count; Female; Humans; Hydroxyurea; Male; Middl | 2001 |
Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Cell Count; Female; Humans; Hydroxyurea; Male; Middl | 2001 |
Therapy-related changes of CD34+ progenitor cells in chronic myeloid leukemia: a morphometric study on sequential trephine biopsies.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Cells; Case-Cont | 2001 |
Therapy-related changes of CD34+ progenitor cells in chronic myeloid leukemia: a morphometric study on sequential trephine biopsies.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Cells; Case-Cont | 2001 |
Unusually prolonged survival of a case of acute megakaryoblastic leukemia secondary to long-standing polycythemia vera.
Topics: Bone Marrow; Combined Modality Therapy; Disease Progression; Erythrocyte Transfusion; Female; Humans | 2002 |
Unusually prolonged survival of a case of acute megakaryoblastic leukemia secondary to long-standing polycythemia vera.
Topics: Bone Marrow; Combined Modality Therapy; Disease Progression; Erythrocyte Transfusion; Female; Humans | 2002 |
Chronic granulocytic leukemia cutis treated with hydroxyurea. Report of a case.
Topics: Female; Humans; Hydroxyurea; Leukemia, Myeloid; Middle Aged; Primary Myelofibrosis; Punctures; Skin | 1978 |
Chronic granulocytic leukemia cutis treated with hydroxyurea. Report of a case.
Topics: Female; Humans; Hydroxyurea; Leukemia, Myeloid; Middle Aged; Primary Myelofibrosis; Punctures; Skin | 1978 |
Skin changes secondary to hydroxyurea therapy.
Topics: Administration, Oral; Adult; Biopsy; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Leukocyte Count | 1975 |
Skin changes secondary to hydroxyurea therapy.
Topics: Administration, Oral; Adult; Biopsy; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Leukocyte Count | 1975 |
Hypercalcemia in idiopathic myelofibrosis: modulation of calcium and collagen homeostasis by 1,25-dihydroxyvitamin D3.
Topics: Adult; Biopsy; Bone Marrow; Calcitriol; Calcium; Collagen; Homeostasis; Humans; Hydroxyurea; Hyperca | 1992 |
Hypercalcemia in idiopathic myelofibrosis: modulation of calcium and collagen homeostasis by 1,25-dihydroxyvitamin D3.
Topics: Adult; Biopsy; Bone Marrow; Calcitriol; Calcium; Collagen; Homeostasis; Humans; Hydroxyurea; Hyperca | 1992 |
Management of myelofibrosis with intermittent hydroxyurea.
Topics: Aged; Aged, 80 and over; Drug Administration Schedule; Female; Humans; Hydroxyurea; Male; Middle Age | 1991 |
Management of myelofibrosis with intermittent hydroxyurea.
Topics: Aged; Aged, 80 and over; Drug Administration Schedule; Female; Humans; Hydroxyurea; Male; Middle Age | 1991 |
Clinical significance of serum pro-collagen III in chronic myeloproliferative disorders.
Topics: Aged; Bloodletting; Humans; Hydroxyurea; Myeloproliferative Disorders; Polycythemia; Polycythemia Ve | 1990 |
Clinical significance of serum pro-collagen III in chronic myeloproliferative disorders.
Topics: Aged; Bloodletting; Humans; Hydroxyurea; Myeloproliferative Disorders; Polycythemia; Polycythemia Ve | 1990 |
Cutaneous extramedullary hematopoiesis with a preponderance of atypical megakaryocytes in myelofibrosis.
Topics: Aged; Biopsy; Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Male; Megakaryocytes; Primary Myel | 1990 |
Cutaneous extramedullary hematopoiesis with a preponderance of atypical megakaryocytes in myelofibrosis.
Topics: Aged; Biopsy; Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Male; Megakaryocytes; Primary Myel | 1990 |
Reversal of myelofibrosis by hydroxyurea.
Topics: Bone Marrow; Follow-Up Studies; Hemoglobins; Humans; Hydroxyurea; Leukocyte Count; Middle Aged; Plat | 1990 |
Reversal of myelofibrosis by hydroxyurea.
Topics: Bone Marrow; Follow-Up Studies; Hemoglobins; Humans; Hydroxyurea; Leukocyte Count; Middle Aged; Plat | 1990 |
The effect of hydroxyurea on hemoglobin F in patients with myeloproliferative syndromes.
Topics: Adult; Aged; Erythrocyte Indices; Female; Fetal Hemoglobin; Humans; Hydroxyurea; Male; Middle Aged; | 1985 |
The effect of hydroxyurea on hemoglobin F in patients with myeloproliferative syndromes.
Topics: Adult; Aged; Erythrocyte Indices; Female; Fetal Hemoglobin; Humans; Hydroxyurea; Male; Middle Aged; | 1985 |
Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia. Results of daily and intermittent fractionation with and without concomitant hydroxyurea.
Topics: Adult; Aged; Child; Evaluation Studies as Topic; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Mal | 1986 |
Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia. Results of daily and intermittent fractionation with and without concomitant hydroxyurea.
Topics: Adult; Aged; Child; Evaluation Studies as Topic; Female; Humans; Hydroxyurea; Leukemia, Myeloid; Mal | 1986 |
Decreased natural killer (NK) activity in patients with myeloproliferative disorders.
Topics: Bloodletting; Humans; Hydroxyurea; Interferon Type I; Interleukin-2; Killer Cells, Natural; Myelopro | 1989 |
Decreased natural killer (NK) activity in patients with myeloproliferative disorders.
Topics: Bloodletting; Humans; Hydroxyurea; Interferon Type I; Interleukin-2; Killer Cells, Natural; Myelopro | 1989 |
Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea.
Topics: Drug Evaluation; Humans; Hydroxyurea; Platelet Count; Polycythemia Vera; Primary Myelofibrosis; Thro | 1988 |
Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea.
Topics: Drug Evaluation; Humans; Hydroxyurea; Platelet Count; Polycythemia Vera; Primary Myelofibrosis; Thro | 1988 |
Small intestinal myeloid metaplasia.
Topics: Aged; Female; Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Intestinal Diseases; Intestine, Sm | 1988 |
Small intestinal myeloid metaplasia.
Topics: Aged; Female; Hematopoiesis, Extramedullary; Humans; Hydroxyurea; Intestinal Diseases; Intestine, Sm | 1988 |
Acute leukemia in polycythemia vera.
Topics: Acute Disease; Antigens, Neoplasm; Bloodletting; Chlorambucil; Chromosome Aberrations; Chromosome Di | 1986 |
Acute leukemia in polycythemia vera.
Topics: Acute Disease; Antigens, Neoplasm; Bloodletting; Chlorambucil; Chromosome Aberrations; Chromosome Di | 1986 |
Hypereosinophilic syndrome associated with polycythemia vera.
Topics: Eosinophilia; Female; Humans; Hydroxyurea; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Re | 1986 |
Hypereosinophilic syndrome associated with polycythemia vera.
Topics: Eosinophilia; Female; Humans; Hydroxyurea; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Re | 1986 |
Hypercalcaemia in the accelerated phase of chronic myelogenous leukaemia: no relationship to the phenotype of the blast cells.
Topics: Adult; Bone Marrow Examination; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Hydroxyu | 1985 |
Hypercalcaemia in the accelerated phase of chronic myelogenous leukaemia: no relationship to the phenotype of the blast cells.
Topics: Adult; Bone Marrow Examination; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Hydroxyu | 1985 |
Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance.
Topics: Anemia; Azauridine; Blood Cell Count; Blood Platelets; Bone Marrow Examination; Busulfan; Cell Trans | 1974 |
Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance.
Topics: Anemia; Azauridine; Blood Cell Count; Blood Platelets; Bone Marrow Examination; Busulfan; Cell Trans | 1974 |